Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiol Young ; 33(8): 1312-1315, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36472120

ABSTRACT

OBJECTIVE: We aimed to evaluate the efficacy of combined (ibuprofen+paracetamol) medical therapy in cases of persistent haemodynamically significant patent ductus arteriosus that are resistant to standard medical monotherapy (ibuprofen and/or paracetamol) in this retrospective multi-centre study. METHODS: The combined therapy included the administration of 15mg/kg/dose of paracetamol every 6 h for 3 days and ibuprofen at an initial dose of 10mg/kg/dose followed by 5 mg/kg/dose every 24 h. After 2 days following the administration of the last dose, the researchers evaluated the efficacy of combined treatment by conducting an echocardiographic examination. RESULTS: Of all 42 patients who received combined therapy, 37 (88.1%) patients exhibited closure of the haemodynamically significant patent ductus arteriosus without requiring surgical ligation. Patients who did not respond to combined therapy had a higher mean birth weight and gestational age compared to those who responded (p < 0.05). CONCLUSION: The researchers believe the success of ibuprofen and paracetamol in haemodynamically significant patent ductus arteriosus treatment may be due to their synergistic efficacy and inhibition of the prostaglandin synthesis pathway through different enzymes. The results of our retrospective trial suggest that combination therapy with paracetamol and ibuprofen can be attempted when monotherapy is unsuccessful in treating haemodynamically significant patent ductus arteriosus, especially in centres without a surgical department.


Subject(s)
Acetaminophen , Ductus Arteriosus, Patent , Ibuprofen , Female , Humans , Infant, Newborn , Male , Acetaminophen/therapeutic use , Drug Therapy, Combination , Ductus Arteriosus, Patent/diagnostic imaging , Ductus Arteriosus, Patent/drug therapy , Ibuprofen/therapeutic use , Retrospective Studies , Treatment Outcome , Echocardiography
2.
Turk J Med Sci ; 53(6): 1786-1793, 2023.
Article in English | MEDLINE | ID: mdl-38813516

ABSTRACT

Background/aim: Hypoxic ischemic encephalopathy (HIE) is one of the common causes of mortality and morbidity in newborns. Despite therapeutic hypothermia, an important treatment with proven efficacy, the morbidity and mortality rates remain high. The aim of this study was to neurodevelopmentally evaluate patients who underwent therapeutic hypothermia. Material and method: Included herein were patients who underwent hypothermia between 2018 and 2020. Their medical files were reviewed retrospectively, and their demographic and clinical information was recorded. Patients whose contact information was available were called to the developmental pediatrics outpatient clinic for a neurodevelopmental evaluation. The Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-III) was used as the evaluation tool. Laboratory values and clinical parameters of the patients were further analyzed. Results: It was found that 42 patients underwent hypothermia in 3 years, of whom 14 (33.3%) had died. Of the 28 patients who were discharged, 20 children could be reached, and a neurodevelopmental evaluation was performed. Developmental delay in the cognitive area was detected in 11 (55%) patients, delay in the language area was found in 9 (45%) patients, and delay in the motor area was found in 11 (55%) patients. The correlation and regression analysis results determined that the time to start cooling was the most effective common factor in all 3 fields of scoring. Conclusion: The time to start cooling is related to the neurodevelopmental outcomes of patients with HIE. The earlier cooling is started, the better the neurodevelopmental results. Despite therapeutic hypothermia, the neurodevelopmental development of infants may be adversely affected. These patients should be followed-up neurodevelopmentally for a long time.


Subject(s)
Hypothermia, Induced , Hypoxia-Ischemia, Brain , Humans , Hypoxia-Ischemia, Brain/therapy , Hypoxia-Ischemia, Brain/diagnosis , Hypothermia, Induced/methods , Male , Female , Infant, Newborn , Retrospective Studies , Neurodevelopmental Disorders/diagnosis , Neurodevelopmental Disorders/etiology , Neurodevelopmental Disorders/epidemiology , Infant , Child, Preschool , Developmental Disabilities/diagnosis , Developmental Disabilities/etiology
3.
Turk J Med Sci ; 52(3): 796-802, 2022 Jun.
Article in English | MEDLINE | ID: mdl-36326343

ABSTRACT

BACKGROUND: Hypoxic-ischemic encephalopathy (HIE) is a condition that may cause multiple organ dysfunction and has a high rate of mortality and morbidity. Therapeutic hypothermia is the only proven treatment that decreases the sequel and mortality rate of neonates that are born after 36 weeks of pregnancy and have moderate-severe HIE. METHODS: Our study was a single-center, retrospective study that includes newborns (gestational age ≥ 36 weeks) who underwent therapeutic hypothermia due to hypoxic-ischemic encephalopathy between 2010 and 2020. We evaluated 125 patients who were diagnosed with moderate to severe HIE and received therapeutic hypothermia. Demographic and clinical data were obtained from electronic medical records and patient files. The patients were separated into two groups as exitus group (n = 39) and discharged group (n = 86). We aimed to evaluate factors affecting mortality. RESULTS: We determined that the median resuscitation times were longer in the delivery room [retrospectively, 10th minutes (0-30) vs. 1 min (0-20), p < 0.05], the tenth min APGAR scores were lower [respectively, 4 (0-7) vs. 6 (3-10), p < 0.05], and the median pH value in the first blood gas taken was lower [respectively, 6.87 (6.4-7.14) vs. 6.90 (6.58-7.12), p < 0.05] in the exitus group. We also determined that multiple organ dysfunction is seen more often in the exitus group. DISCUSSION: This study demonstrated that the depth of acidosis in the blood gas, multiple organ dysfunction, and the existence of early-onset seizures are the signs of poor prognosis. Therefore, physicians need to be aware of such prognostic factors to follow these patients more closely in terms of possible complications and to inform their parents.


Subject(s)
Hypothermia, Induced , Hypoxia-Ischemia, Brain , Pregnancy , Female , Humans , Infant, Newborn , Infant , Hypoxia-Ischemia, Brain/therapy , Hypoxia-Ischemia, Brain/diagnosis , Retrospective Studies , Multiple Organ Failure , Hypothermia, Induced/adverse effects , Apgar Score
4.
BMJ Case Rep ; 20112011 Mar 15.
Article in English | MEDLINE | ID: mdl-22698901

ABSTRACT

In this report, an 8-year-old girl is presented with the complaint of progressive night blindness. The authors have performed eye funduscopy, which showed chorioretinal atrophy in gyrate shape. A high level of plasma ornithine was determined. Urinary excretion of ornithine as well as lysine and cystine were increased. Patient was treated with high dose pyridoxine supplement (500 mg/dl). The night blindness condition of the patient improved. After 1 month of pyridoxine therapy ornithine level of her plasma was successfully reduced and blindness improved.


Subject(s)
Gyrate Atrophy/diagnosis , Pyridoxine/therapeutic use , Vitamin B Complex/therapeutic use , Biomarkers/blood , Biomarkers/urine , Child , Cystinuria/etiology , Female , Gyrate Atrophy/blood , Gyrate Atrophy/drug therapy , Gyrate Atrophy/urine , Humans , Lysine/urine , Night Blindness/etiology , Ornithine/blood , Ornithine/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...